Male-pattern hair loss affects 80% of men at some point in their lifetime, while female-pattern hair loss affects half of all women over the age of 70. But “until recently, we knew remarkably little about how to slow, halt and reverse its seemingly inevitable onset,” said BBC Science Focus.
For all the recent messaging about “body positivity,” the search for a balding “fix” has become “increasingly desperate and financially lucrative,” said Esquire. The hair-loss industry is well on track to be worth $12 billion by 2030.
An “early front-runner” in the anti-baldness race is hair cloning, said Howarth. Also known as hair multiplication, it’s a form of “hair banking.” Before baldness hits, healthy hair follicles are extracted from your scalp and cryogenically frozen. Once hair-thinning begins, these follicles are taken to a lab, and the skin cells around them are isolated and multiplied.
In Japan, researchers are successfully growing hair follicles from scratch in a lab. But the “big one” is a drug called PP405, developed by U.S. pharmaceutical company Pelage, said New York Magazine. “We were blown away,” Qing Yu Christina Weng, Pelage’s chief medical officer, told the magazine. After four weeks of applying the drug as a topical gel, not only was the treatment group “growing new hair where there wasn’t any before,” but it wasn’t “peach fuzz or baby hair.” It was “proper, thick, terminal hair.”
If the drug lives up to the initial hype, its potential is obvious. “After decades of snake oil and broken promises,” it feels as though the “end of baldness” is within sight, said New York. Call it the “faint stubble of hope.”
|